Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Aug;8(3):209-14.
doi: 10.2174/157340312803217148.

Treating and preventing no reflow in the cardiac catheterization laboratory

Ryan Berg  1 , Cyrus Buhari
Affiliations
Review

Treating and preventing no reflow in the cardiac catheterization laboratory

Ryan Berg et al. Curr Cardiol Rev. 2012 Aug.

Abstract

The no reflow phenomenon can happen during elective or primary percutaneous coronary intervention. This phenomenon is thought to be a complex process involving multiple factors that eventually lead to microvascular obstruction and endothelial disruption. Key pathogenic components include distal atherothrombotic embolization, ischemic injury, reperfusion injury, and susceptibility of coronary microcirculation to injury. Thus, pharmacologic and mechanical strategies to prevent and treat no reflow target these mechanisms. Specifically, pharmacologic therapy consisting of vasodilators and antiplatelet agents have shown benefit in the treatment of no-reflow and mechanical therapies such as distal protection and aspiration thrombectomy have also shown benefit.

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Myocardial targets for pharmacological therapies to prevent no-reflow. The inset depicts a myocardial cell and its subcellular structures involved in cardioprotective pathways. Adapted with permission from Jaffe R, Dick A, and Strauss B. Prevention and Treatment of Microvascular Obstruction-Related Myocardial Injury and Coronary No-Reflow Following Percutaneous Coronary Intervention. A Systematic Approach. J Am Coll Cardiol Intv 2010;3:695-704.
Fig. (2)
Fig. (2)
Mechanical strategies to prevent no-reflow. The inset depicts aspirated thrombus. Adapted with permission from Jaffe R, Dick A, and Strauss B. Prevention and Treatment of Microvascular Obstruction-Related Myocardial Injury and Coronary No-Reflow Following Percutaneous Coronary Intervention. A Systematic Approach. J Am Coll Cardiol Intv 2010; 3: 695-704.
Fig. (3)
Fig. (3)
Algorithm for prevention and treatment of no-reflow. PCI=Percutaneous Coronary Intervention, SVG=Saphenous Vein Grafts, IC=Intracoronary
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lee CH, Wong HB, Tan HC, et al. Impact of reversibility of no reflow phenomenonon 30-day mortality following percutaneous revascularizationfor acute myocardial infarction-insights from a 1,328patient registry. J Interv Cardiol. 2005;18:261–266. - PubMed
    1. Levine GN, Bates ER, Blakenship JC, et al. 2011 ACCF/AHA/ SCAI Guideline for Percutaneous Coronary Intervention: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J. Am Coll Cardiol. 2011;58:e44–e122. - PubMed
    1. Marzilli M, Orsini E, Marraccini P, et al. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation. 2000;101:2154–9. - PubMed
    1. Mahaffey KW, Puma JA, Barbagelata NA, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: re-sults of a multicenter, randomized, placebo-controlled trial: theAcute Myocardial Infarction STudy of ADenosine (AMISTAD)trial. J Am Coll Cardiol. 1999;34:1711–20. - PubMed
    1. Ross AM, Gibbons RJ, Stone GW. AMISTAD-II Investigators. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct toreperfusion in the treatment of acute myocardial infarction(AMISTAD-II) J Am Coll Cardiol. 2005;45:1775–80. - PubMed

MeSH terms

Substances